Manasanch E.E.,U.S. National Institutes of Health |
Korde N.,U.S. National Institutes of Health |
Zingone A.,U.S. National Institutes of Health |
Tageja N.,U.S. National Institutes of Health |
And 5 more authors.
Leukemia and Lymphoma | Year: 2014
Since the early 1990s, the synthesis and subsequent clinical application of small molecule inhibitors of the ubiquitin proteasome pathway (UPP) has revolutionized the treatment and prognosis of multiple myeloma. In this review, we summarize important aspects of the biology of the UPP with a focus on its structure and key upstream/downstream regulatory components. We then review current knowledge of plasma cell sensitivity to proteasome inhibition and highlight new proteasome inhibitors that have recently entered clinical development. Lastly, we address the putative role of circulating proteasomes as a novel biomarker in multiple myeloma and provide guidance for future clinical trials using proteasome inhibitors. © 2014 Informa UK, Ltd.